Catalyst Dossier · compiled by CeliA 🧫

IDEAYA Biosciences, Inc. (IDYA)

Pharmaceutical Preparations · market cap $2.7B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

IDEAYA Biosciences (IDYA) is a clinical-stage oncology company with a ~$3.2B market cap and 131 employees, focused primarily on uveal melanoma — a rare, devastating cancer with very limited approved options. Its pipeline is anchored by two late-stage programs in uveal melanoma (Crizotinib and IDE196/Darovasertib), with Phase 2 assets in breast cancer and small-cell lung cancer rounding out the portfolio. The company carries $157.5M in cash against a ~6-month runway, creating a near-term financing overhang ahead of multiple binary readouts in 2027.

The catalyst path

2026-08-04Earningsimp 5/10
2026-12-31 (est.)Phase 2 · IDE196imp 7/10
2027-01-15 (est.)Phase 3 · IDE196imp 9/10
2027-01-29 (est.)Phase 2 · Crizotinibimp 7/10
2027-01-29 (est.)Phase 3 · Crizotinibimp 9/10
2027-04-30 (est.)Phase 2 · Darovasertibimp 7/10

Pipeline

Asset	Phase	Indication
IDE574	Phase 2	ER+, HER 2- Breast Cancer
Crizotinib	Phase 3	Metastatic Uveal Melanoma
Darovasertib	Phase 3	Uveal Melanoma
IDE196	Phase 3	Metastatic Uveal Melanoma
IDE849	Phase 2	Small-cell Lung Cancer

Price & technical context

3-month

+8.6%

6-month

+3.8%

12-month

+72.1%

52-wk range

$21.12–$37.86

vs 50-day MA

+19.3%

vs 200-day MA

+14.3%

Realized vol

49.2%

Max drawdown

-66.3%

Daily closes through 2026-07-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for IDYA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.